Literature DB >> 31563901

MicroRNA-296-5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2-Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer.

Jun Okazaki1, Toshihito Tanahashi1, Yasushi Sato1, Jinsei Miyoshi1, Tadahiko Nakagawa1, Tetsuo Kimura1, Hiroshi Miyamoto1, Yasuteru Fujino1, Fumika Nakamura1, Masanori Takehara1, Beibei Ma1, Masahiro Bando1, Shinji Kitamura1, Koichi Okamoto1, Naoki Muguruma1, Masahiro Sogabe1, Tetsuji Takayama2.   

Abstract

BACKGROUND/AIMS: Pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive invasion, early metastasis, and resistance to chemotherapy, leading to a poor prognosis. To clarify the molecular mechanism of these malignant characteristics, we performed a genome-wide microRNA (miRNA) array analysis utilizing micro-cancer tissues from patients with unresectable PDAC (stage IV), obtained by endoscopic ultrasound-fine needle aspiration (EUS-FNA).
METHODS: The expression profiles of 2,042 miRNAs were determined using micro-cancer tissues from 13 patients with unresectable PDAC obtained by EUS-FNA. The relationship between individual miRNA levels and overall survival (OS) was analyzed. Possible target genes for miRNAs were bioinformatically analyzed using the online database miRDB. Pancreatic cancer cell lines PANC-1, MIA PaCa-2, and PK-8 were transfected with miRNA mimic or small interfering RNA, and cell invasion, epithelial-mesenchymal transition (EMT), and apoptosis markers were examined. miRNA and mRNA expressions were examined by quantitative polymerase chain reaction.
RESULTS: Of 2,042 miRNAs, the 10 that exhibited the lowest correlation coefficient (p ≤ 0.005) between miRNA expression level and OS among the patients were identified. The miRDB and expression analysis in cancer cell lines for the 10 miRNAs identified miR-296-5p and miR-1207-5p as biomarkers predictive of shorter survival (p < 0.0005). Bioinformative target gene analysis and transfection experiments with miRNA mimics showed that Bcl2-related ovarian killer (BOK), a pro-apoptotic gene, is a target for miR296-5p in pancreatic cancer cells; transfection of miR-296-5p mimic into PANC-1, MIA PaCa-2, and PK-8 cells resulted in significant suppression of BOK mRNA and protein expression. These transfectants showed significantly higher invasion capability compared with control cells, and knock down of BOK in pancreatic cancer cells similarly enhanced invasion capability. Transfectants of miR-296-5p mimic also exhibited aberrant expression of EMT markers, including vimentin and N-cadherin. Moreover, these transfectants showed a significantly lower apoptosis rate in response to 5-fluorouracil and gemcitabine with a decrease of BOK expression, suggesting a role of miR-296-5p in drug resistance.
CONCLUSION: These results suggest that miR-296-5p is a useful biomarker for a poor prognosis in patients with PDAC, and that the miR-296-5p/BOK signaling axis plays an important role in cell invasion, drug resistance, and EMT in PDACs.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Apoptosis; Biomarker; Epithelial-mesenchymal transition; MicroRNA; Pancreatic cancer

Mesh:

Substances:

Year:  2019        PMID: 31563901     DOI: 10.1159/000503225

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  7 in total

1.  LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.

Authors:  Yasuyuki Okada; Naoki Takahashi; Tetsuji Takayama; Ajay Goel
Journal:  Carcinogenesis       Date:  2021-04-30       Impact factor: 4.944

2.  circRNA circ_102049 Implicates in Pancreatic Ductal Adenocarcinoma Progression through Activating CD80 by Targeting miR-455-3p.

Authors:  Jie Zhu; Yong Zhou; Shanshan Zhu; Fei Li; Jiajia Xu; Liming Zhang; Hairong Shu
Journal:  Mediators Inflamm       Date:  2021-01-07       Impact factor: 4.711

Review 3.  EMT-associated microRNAs and their roles in cancer stemness and drug resistance.

Authors:  Guangtao Pan; Yuhan Liu; Luorui Shang; Fangyuan Zhou; Shenglan Yang
Journal:  Cancer Commun (Lond)       Date:  2021-01-27

Review 4.  Noncoding RNAs Associated with Therapeutic Resistance in Pancreatic Cancer.

Authors:  Seung Wan Son; Mun Gyu Song; Ba Da Yun; Jong Kook Park
Journal:  Biomedicines       Date:  2021-03-07

5.  Integrative analysis of TCGA data identifies miRNAs as drug-specific survival biomarkers.

Authors:  Shuting Lin; Jie Zhou; Yiqiong Xiao; Bridget Neary; Yong Teng; Peng Qiu
Journal:  Sci Rep       Date:  2022-04-26       Impact factor: 4.996

Review 6.  Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications.

Authors:  Xuehao Zhou; Xiang Ao; Zhaojun Jia; Yiwen Li; Shouxiang Kuang; Chengcheng Du; Jinyu Zhang; Jianxun Wang; Ying Liu
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

Review 7.  miRNA-based biomarkers, therapies, and resistance in Cancer.

Authors:  Boxue He; Zhenyu Zhao; Qidong Cai; Yuqian Zhang; Pengfei Zhang; Shuai Shi; Hui Xie; Xiong Peng; Wei Yin; Yongguang Tao; Xiang Wang
Journal:  Int J Biol Sci       Date:  2020-07-19       Impact factor: 6.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.